The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease
Open accessAbstract
BACKGROUND: Interstitial lung disease (ILD) is a common manifestation of systemic sclerosis and a leading cause of systemic sclerosis-related death. Nintedanib, a tyrosine kinase inhibitor, has been shown to have antifibrotic and antiinflammatory effects in preclinical models of systemic sclerosis and ILD. METHODS: We conducted a randomized, double-blind, placebo-controlled trial to investigate the efficacy and safety of nintedanib in patients with ILD associated with systemic sclerosis. Patients who had systemic sclerosis with an onset of the first non-Raynaud's symptom within the past 7 years and a high-resolution computed tomographic scan that showed fibrosis affecting at least 10% of the lungs were randomly assigned, in a 1:1 ratio, to receive 150 mg of nintedanib, administered orally twice daily, or placebo. The primary end point was the annual rate of decline in forced vital capacity (FVC), assessed over a 52-week period. Key secondary end points were absolute changes from baseline in the modified Rodnan skin score and in the total score on the St. George's Respiratory Questionnaire (SGRQ) at week 52. RESULTS: A total of 576 patients received at least one dose of nintedanib or placebo; 51.9% had diffuse cutaneous systemic sclerosis, and 48.4% were receiving mycophenolate at baseline. In the primary end-point analysis, the adjusted annual rate of change in FVC was -52.4 ml per year in the nintedanib group and -93.3 ml per year in the placebo group (difference, 41.0 ml per year; 95% confidence interval [CI], 2.9 to 79.0; P = 0.04). Sensitivity analyses based on multiple imputation for missing data yielded P values for the primary end point ranging from 0.06 to 0.10. The change from baseline in the modified Rodnan skin score and the total score on the SGRQ at week 52 did not differ significantly between the trial groups, with differences of -0.21 (95% CI, -0.94 to 0.53; P = 0.58) and 1.69 (95% CI, -0.73 to 4.12 [not adjusted for multiple comparisons]), respectively. Diarrhea, the most common adverse event, was reported in 75.7% of the patients in the nintedanib group and in 31.6% of those in the placebo group. CONCLUSIONS: Among patients with ILD associated with systemic sclerosis, the annual rate of decline in FVC was lower with nintedanib than with placebo; no clinical benefit of nintedanib was observed for other manifestations of systemic sclerosis. The adverse-event profile of nintedanib observed in this trial was similar to that observed in patients with idiopathic pulmonary fibrosis; gastrointestinal adverse events, including diarrhea, were more common with nintedanib than with placebo. (Funded by Boehringer Ingelheim; SENSCIS ClinicalTrials.gov number, NCT02597933.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“This observation is therefore in accordance with recent clinical trials showing that antifibrotic therapies are effective in progressive fibrotic interstitial lung diseases other than IPF [20,26,27].”
In the citing paper
“nintedanib has also now been approved for systemic sclerosis (SSc)-associated ILD (SSc-ILD), based on the positive outcome of Safety and Efficacy of Nintedanib in Systemic Sclerosis (SENSCIS) trial (Distler et al., 2019).”
From Pulmonary fibrosis: Emerging diagnostic and therapeutic strategies (2023) · cites this paper as Distler et al., 2019
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654
Self-citationvan den Hoogen, F. H. J., Khanna, D., Fransen, J., Johnson, S. R., Baron, M. G., Tyndall, A., Matucci‐Cerinic, M., Naden, R. P., Medsger, T. A., Carreira, P. E., et al. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-204424 · Cited by 2,881
Self-citationThe St George's Respiratory Questionnaire
Jones, P., Quirk, F. H., & Baveystock, C. M. (1991) · Respiratory Medicine · doi:10.1016/s0954-6111(06)80166-6 · Cited by 2,729
Cyclophosphamide versus placebo in scleroderma lung disease
Tashkin, D. P., Elashoff, R., Clements, P. J., Goldin, J., Roth, M. D., Furst, D. E., Arriola, E., Silver, R., Strange, C., Bolster, M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055120 · Cited by 1,677
Self-citationInterstitial Lung Disease in Systemic Sclerosis
Goh, N. S. L., Desai, S. R., Veeraraghavan, S., Hansell, D. M., Copley, S. J., Maher, T. M., Corte, T. J., Sander, C. R., Ratoff, J. C., Devaraj, A., et al. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200706-877oc · Cited by 1,249
Self-citationEfficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
Richeldi, L., Costabel, U., Selman, M., Kim, D. S., Hansell, D. M., Nicholson, A. G., Brown, K. K., Flaherty, K. R., Noble, P. W., Raghu, G., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103690 · Cited by 1,157
Self-citationTashkin, D. P., Roth, M. D., Clements, P. J., Furst, D. E., Khanna, D., Kleerup, E. C., Goldin, J. G., Arriola, E., Volkmann, E. R., Kafaja, S., et al. (2016) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(16)30152-7 · Cited by 1,077
Self-citationMode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis
Wollin, L., Wex, E., Pautsch, A., Schnapp, G., Hostettler, K. E., Stowasser, S., & Kolb, M. (2015) · European Respiratory Journal · doi:10.1183/09031936.00174914 · Cited by 1,005
Self-citationWalker, U. A., Tyndall, A., Czirják, L., Denton, C. P., Farge, D., Kowal‐Bielecka, O., Müller‐Ladner, U., Bocelli‐Tyndall, C., & Matucci‐Cerinic, M. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.062901 · Cited by 927
Cited by
Sorted by citations
Items 901–1,000 of 1,000
Diagnosis of pleuroparenchymal fibroelastosis: A review
Tetikkurt, C., Öztürk, B. Ç., & Güngördü, N. (2022) · Monaldi Archives for Chest Disease · doi:10.4081/monaldi.2022.2363 · Cited by 4
Serum Immunoglobulin G (IgG) Subclasses in a Cohort of Systemic Sclerosis Patients
Pellicano, C., Colalillo, A., Cusano, G., Palladino, A., Pellegrini, M., Callà, C. A. M., Mazzuccato, G., Carnazzo, V., Pignalosa, S., Biase, L. D., et al. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13020309 · Cited by 4
Shen, L., Yin, H., Sun, L., Zhang, Z., Jin, Y., Cao, S., Fu, Q., Fan, C., Bao, C., Lu, L., et al. (2023) · Arthritis Research & Therapy · doi:10.1186/s13075-023-03135-2 · Cited by 4
Planas‐Cerezales, L., Fabbri, L., & Pearmain, L. (2023) · Breathe · doi:10.1183/20734735.0090-2023 · Cited by 4
Jiao, T., Wang, Y., Lin, X., Song, W., Wang, L., Tapu, S. R., Xu, L., Nie, L., Zhang, Q., & Li, J. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1256156 · Cited by 4
Hirose, H., Higuchi, T., Takagi, K., Tochimoto, A., Ichimura, Y., Katsumata, Y., Harigai, M., & Kawaguchi, Y. (2023) · International Journal of Rheumatic Diseases · doi:10.1111/1756-185x.14978 · Cited by 4
Challenges in evidence-based therapy for systemic sclerosis associated interstitial lung disease
Denton, C. P., & Ong, V. H. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30012-6 · Cited by 4
Min, H. K., Kim, S., Lee, S., & Kim, H. (2020) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2020.443 · Cited by 4
Diarrhoea in systemic sclerosis patients as a nocebo effect of nintedanib
Bournia, V.-K., Distler, O., Kravvariti, E., Mitsikostas, D. D., & Sfikakis, P. P. (2020) · European Respiratory Journal · doi:10.1183/13993003.03021-2020 · Cited by 4
Self-citationSumi, T., Uehara, H., Tada, M., Keira, Y., Kamada, K., Shijubou, N., Yamada, Y., Nakata, H., Mori, Y., & Chiba, H. (2021) · Respirology Case Reports · doi:10.1002/rcr2.716 · Cited by 4
Maćkiewicz, B., Lemieszek, M. K., & Dutkiewicz, J. K. (2021) · Annals of Agricultural and Environmental Medicine · doi:10.26444/aaem/133896 · Cited by 4
Systemic Sclerosis and Pulmonary Disease
Ngo, K. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-63046-1_10 · Cited by 4
Rational repurposing of tocilizumab for treatment of lung fibrosis in systemic sclerosis
Denton, C. P., & Khanna, D. (2021) · The Lancet Rheumatology · doi:10.1016/s2665-9913(21)00111-9 · Cited by 4
Hughes, M., & Khanna, D. (2021) · The Lancet Rheumatology · doi:10.1016/s2665-9913(21)00149-1 · Cited by 4
Morgan, K., Woollard, C., Beinart, D., Host, L., & Roddy, J. (2022) · Internal Medicine Journal · doi:10.1111/imj.15832 · Cited by 4
Hoffmann, T., Gaßler, N., Teichgräber, U. K.-M., Sandhaus, T., Oelzner, P., Wolf, G., & Pfeil, A. (2022) · ACR Open Rheumatology · doi:10.1002/acr2.11516 · Cited by 4
Beketova, T. V., Golovina, О. A., & Avdeeva, A. S. (2023) · Rheumatology Science and Practice · doi:10.47360/1995-4484-2023-62-69 · Cited by 4
What is new in the treatment of interstitial lung diseases
Sotiropoulou, V., Karampitsakos, T., Katsaras, M., Παπαϊωάννου, Ο., Tsiri, P., Sampsonas, F., & Tzouvelekis, A. (2023) · Pneumon · doi:10.18332/pne/161867 · Cited by 4
Mendoza, F. A., Allawh, T., & Jiménez, S. A. (2022) · Clinical and Experimental Rheumatology · doi:10.55563/clinexprheumatol/am4nmv · Cited by 4
Clinical significance of high monocyte counts for the continuous treatment with nintedanib
Tsuneyoshi, S., Zaizen, Y., Tominaga, M., Matama, G., Umemoto, S., Ohno, S., Takaki, R., Yano, R., Murotani, K., Okamoto, M., et al. (2023) · BMC Pulmonary Medicine · doi:10.1186/s12890-023-02536-y · Cited by 4
The Role of CCL24 in Systemic Sclerosis
Levy‐Barazany, H., Gluschnaider, U., & Balbir‐Gurman, A. (2023) · Rambam Maimonides Medical Journal · doi:10.5041/rmmj.10504 · Cited by 4
Woo, S., Gandhi, S., Ghincea, A., Saber, T., Lee, C., & Ryu, C. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1254904 · Cited by 4
Takuma, S., Suzuki, Y., Kono, M., Hasegawa, H., Hashimoto, D., Yokomura, K., Mori, K., Shimizu, M., Inoue, Y., Yasui, H., et al. (2024) · Respiratory Medicine · doi:10.1016/j.rmed.2024.107542 · Cited by 4
Interstitielle Lungenerkrankungen
Soriano, D. B., Nattenmüller, J., Schröder, K., Schygulla, E., Jouanjan, L., Venhoff, N., Jandova, I., Stolz, D., & Frye, B. C. (2024) · Die Radiologie · doi:10.1007/s00117-024-01340-x · Cited by 4
Therapie der systemischen Sklerose-assoziierten interstitiellen Lungenerkrankung
Prasse, A., Bonella, F., Müller‐Ladner, U., Witte, T., Hunzelmann, N., & Distler, J. H. W. (2019) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-019-00724-y · Cited by 4
Τzouvelekis, Α., & Bouros, D. E. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2019.11.052 · Cited by 4
Practice guidelines for interstitial lung diseases: Widening the reach
Montesi, S. B. (2020) · Lung India · doi:10.4103/lungindia.lungindia_487_20 · Cited by 4
Toward Realizing the Full Potential of Registries in Interstitial Lung Disease
Durheim, M. T. (2020) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202008-1077ed · Cited by 4
The evolution of the European Respiratory Journal : weathering the publishing pandemic
Kolb, M. R. J., Chalmers, J. D., & Humbert, M. J. C. (2021) · European Respiratory Journal · doi:10.1183/13993003.00084-2021 · Cited by 4
Promise and challenge of systemic sclerosis therapies
Kawano, Y., & Chung, L. S. (2021) · Nature Reviews Rheumatology · doi:10.1038/s41584-021-00678-z · Cited by 4
Campochiaro, C., & Matucci‐Cerinic, M. (2023) · Rheumatology · doi:10.1093/rheumatology/kead504 · Cited by 4
Basaran, E., Karadağ, D. T., Çakır, Ö., Gökçen, N., Yazici, A., & Çefle, A. (2024) · Clinical Rheumatology · doi:10.1007/s10067-024-06950-3 · Cited by 3
Blamont, E., Farrington, S., Glover-Southworth, N., Cornwell, G., Gibson, L., Sloan, M. A., & Hughes, M. (2024) · Rheumatology Advances in Practice · doi:10.1093/rap/rkae152 · Cited by 3
Hong, M., Veitch, E. M., & Limaye, S. (2025) · Internal Medicine Journal · doi:10.1111/imj.70026 · Cited by 3
Therapeutic options for patients with pulmonary hypertension and interstitial lung disease
Swisher, J. W., & Weaver, E. (2025) · Therapeutic Advances in Respiratory Disease · doi:10.1177/17534666251335815 · Cited by 3
Case‐Based Immunology: B Cells and Systemic Sclerosis Interstitial Lung Disease
Goldman, N. R., Ong, V. H., & Denton, C. P. (2025) · Arthritis & Rheumatology · doi:10.1002/art.43326 · Cited by 3
Yu, W.-K., Yang, Y.-P., Shen, H., Shen, H.-C., Chiou, S.-H., Ko, Y., Su, V. Y., Su, V. Y.-F., & Yang, K. (2025) · Respiratory Investigation · doi:10.1016/j.resinv.2025.07.005 · Cited by 3
Patients With Inflammatory Bowel Disease Are at Increased Risk of Interstitial Lung Diseases
Kochar, B. D., Sun, J., Olén, O., Halfvarson, J., Thuresson, M., Hallowell, R. W., & Ludvigsson, J. F. (2025) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000003699 · Cited by 3
Gogali, A., Κostikas, Κ., & Τzouvelekis, Α. (2025) · European Respiratory Review · doi:10.1183/16000617.0023-2025 · Cited by 3
Fibrosis mechanisms and updates in potential therapeutic targets in systemic sclerosis
Han, X., Wang, X., Huang, J., & Yang, J. Y. (2025) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2025.152811 · Cited by 3
Crotti, C., Ughi, N., Scirè, C. A., Luppi, F., Atzeni, F., Bosello, S. L., Caporali, R. F., Carotti, M., Carrara, G., Cassone, G., et al. (2025) · Reumatismo · doi:10.4081/reumatismo.2025.1865 · Cited by 3
Li, Z., Huan, W., Liu, X., Zhang, K., Wang, X., Huang, Y., Zhou, Q., Huang, S., Sang, Z., & Luo, H. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02407 · Cited by 3
Ni, B., Gong, Y., Li, B., Qiu, L., He, K., Guo, J., Fang, H., Gao, M., Chen, M., Wei, C., et al. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1635809 · Cited by 3
Systemic Sclerosis-Associated Interstitial Lung Disease
Esposito, A. J., Selvan, K. C., Richardson, C., Khanna, D., Bemiss, B., Bernstein, E. J., Chung, J. H., Cox, C. W., Dematte, J. E., Denton, C. P., et al. (2025) · CHEST Journal · doi:10.1016/j.chest.2025.11.047 · Cited by 3
Self-citationMorrisroe, K., & Baron, M. (2026) · European Respiratory Review · doi:10.1183/16000617.0273-2024 · Cited by 3
Muscato, G., Libra, A., Reina, C., Gili, E., Fruciano, M., Martella, S., Palmucci, S., Spicuzza, L., Sambataro, G., & Vancheri, C. (2026) · BMC Pulmonary Medicine · doi:10.1186/s12890-026-04120-6 · Cited by 3
Lee, S.-C., Yu, K.-H., Huang, H., & Juan, H. (2026) · Drug Discovery Today · doi:10.1016/j.drudis.2026.104620 · Cited by 3
Targeting the epithelium in pulmonary fibrosis
Lizé, M., Mayr, C. H., Bleck, M., Wollin, L., Wohnhaas, C. T., Shalashova, I., Olbrich, H., Heilker, R., Engler, A., Bammert, M., et al. (2026) · European Respiratory Review · doi:10.1183/16000617.0225-2025 · Cited by 3
Progressive pulmonary fibrosis: a state-of-the-art review
Cottin, V., Brown, K. K., Flaherty, K. R., Kolb, M. R. J., Lynch, D. A., Oldham, J. M., Valenzuela, C., Wijsenbeek, M. S., & Wells, A. U. (2026) · European Respiratory Journal · doi:10.1183/13993003.01557-2025 · Cited by 3
Drugs that act on the respiratory tract
Yogaratnam, D., Carey, K. M., Coppenrath, V. A., Dawson, A., Harris, M., LaMothe, A. B. W., Pourhosseini, P., & Lynch, A. M. (2021) · Side effects of drugs annual · doi:10.1016/bs.seda.2021.09.001 · Cited by 3
Interstitial Pneumonia with Autoimmune Features
Santhanam, S., Mohanasundaram, K., & Shanmuganandan, K. (2020) · The Journal of the Royal College of Physicians of Edinburgh · doi:10.4997/jrcpe.2020.307 · Cited by 3
Rituximab for connective tissue disease-associated interstitial lung disease
Manfredi, A., Salvarani, C., & Sebastiani, M. (2022) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(22)00356-3 · Cited by 3
Pelechas, E., Kaltsonoudis, E., Voulgari, P. V., & Drosos, A. A. (2023) · Springer eBooks · doi:10.1007/978-3-031-47379-1_11 · Cited by 3
Faber, A.-M., Krieg, T. M., & Hunzelmann, N. (2024) · Die Dermatologie · doi:10.1007/s00105-024-05298-8 · Cited by 3
Can we define difficult-to-treat systemic sclerosis?
Szűcs, G., Szekanecz, Z., & Szamosi, S. (2024) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2024.2352450 · Cited by 3
Yun, C.-X., Huan, M., Zhu, X., Wan, Y.-H., Zou, J., & Zhang, B. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.124302 · Cited by 3
Clinical implications of nintedanib pharmacokinetics in patients with pulmonary fibrosis
Agema, B. C., Berrich, M., Seuren, L., Sassen, S. D. T., Miedema, J. R., Koch, B. C. P., Wijsenbeek, M. S., Koolen, S. L. W., Mathijssen, R. H. J., & Veerman, G. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117341 · Cited by 3
Patient perspectives on educational needs in scleroderma-interstitial lung disease
Savvaides, T. M., Vitantonio, T. A. D., Edgar, A., O’Beirne, R., Krishnan, J. K., Kaner, R. J., Podolanczuk, A. J., Spiera, R., Gordon, J., Safford, M. M., et al. (2025) · Journal of Scleroderma and Related Disorders · doi:10.1177/23971983241303655 · Cited by 3
Ponniah, T., Wong, C. K., Ng, C. M., & Raja, J. (2025) · Journal of Scleroderma and Related Disorders · doi:10.1177/23971983251318827 · Cited by 3
Cardillo, C., Criner, G. J., & Gayen, S. K. (2025) · Therapeutic Advances in Respiratory Disease · doi:10.1177/17534666251326743 · Cited by 3
Gunes, I., Bernstein, E. J., Cowper, S. E., Panse, G., Pradhan, N., Camacho, L. D., Page, N., Bundschuh, E., Williams, A., Carns, M. A., et al. (2025) · Arthritis Research & Therapy · doi:10.1186/s13075-025-03508-9 · Cited by 3
Advances in management of pulmonary fibrosis
Lachowicz, J. A., Steinfort, D., Smallwood, N., & Prasad, J. D. (2025) · Internal Medicine Journal · doi:10.1111/imj.70051 · Cited by 3
Perioperative nintedanib for lung resection in patients with idiopathic pulmonary fibrosis
Sumiya, R., Banno, T., Ueno, H., Hirayama, S., & Suzuki, K. (2025) · Molecular and Clinical Oncology · doi:10.3892/mco.2025.2854 · Cited by 3
Pellicano, C., Villa, A., Carnazzo, V., D’Ippolito, G., Vinante, I., Laterza, F., Basile, U., Rosato, E., & Gigante, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26094290 · Cited by 3
The fibrosis puzzle of systemic sclerosis-associated ILD and the quest for targeted interventions
Doskaliuk, B., Zaiats, L., Sahan, N. T., Fedorchenko, Y., Antymys, O., & Yatsyshyn, R. (2025) · Therapeutic Advances in Respiratory Disease · doi:10.1177/17534666251366023 · Cited by 3
A CD57+CD8+ T cell subset links T cell cytotoxicity to fibrotic lung disease in systemic sclerosis
Sasaki, T., Cao, Y., Sowerby, J. M., Higashioka, K., Marks, K. E., Elahee, M., Kamiya, M., Dellaripa, P. F., Ainsworth, R. I., Taylor, K. E., et al. (2026) · Journal of Clinical Investigation · doi:10.1172/jci194288 · Cited by 4
Chronic fibrosing interstitial lung diseases according to the register of Irkutsk (Russia)
Nashatyreva, M. S., Николаевна, Т. И., & Chernyak, B. A. (2022) · PULMONOLOGIYA · doi:10.18093/0869-0189-2022-32-2-199-207 · Cited by 3
A cysteine proteinase inhibitor ALLN alleviates bleomycin-induced skin and lung fibrosis
Kasamatsu, H., Chino, T., Hasegawa, T., Utsunomiya, N., Utsunomiya, A., Yamada, M., Oyama, N., & Hasegawa, M. (2023) · Arthritis Research & Therapy · doi:10.1186/s13075-023-03130-7 · Cited by 3
Rituximab in the treatment of systemic sclerosis. Literature review
GARZANOVA, L. (2023) · Rheumatology Science and Practice · doi:10.47360/1995-4484-2023-466-474 · Cited by 3
Complications of fibrotic interstitial lung disease for the general radiologist
Watson, S., Dixon, G., Savill, A., Gibbons, M., Barratt, S. L., & Rodrigues, J. C. L. (2024) · Clinical Radiology · doi:10.1016/j.crad.2024.01.015 · Cited by 4
Imai, M., Okabayashi, H., Akaike, K., Hamada, S., Masunaga, A., Ichiyasu, H., & Sakagami, T. (2024) · Respiratory Investigation · doi:10.1016/j.resinv.2024.01.013 · Cited by 3
Behera, A. K., Sharma, P. S., Ranganath, T. G., Kumar, V., Pati, S. K., & Sinha, K. (2024) · Cureus · doi:10.7759/cureus.65579 · Cited by 3
The Saga of Recombinant Human Pentraxin-2 as a Potential Therapeutic Agent for Pulmonary Fibrosis
Meyer, K. C. (2024) · Touch reviews in respiratory & pulmonary diseases. · doi:10.17925/usprd.2024.9.1.4 · Cited by 3
Fujiwara, M., Ikesue, H., Yamaoka, K., Uchida, M., Uesawa, Y., Muroi, N., & Shimizu, T. (2024) · In Vivo · doi:10.21873/invivo.13841 · Cited by 3
Wan, Y., Li, W., Zhu, H., Ai, S., & Lin, W. (2025) · Journal of Materials Chemistry B · doi:10.1039/d5tb00183h · Cited by 3
Fijołek, J., & Śniady, A. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14134631 · Cited by 3
Autologe hämatopoetische Stammzelltransplantation bei systemischer Sklerose
Alexander, T., Henes, J. C., Distler, J. H. W., Schmalzing, M., Blank, N., Kötter, I., & Hiepe, F. (2020) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-020-00789-0 · Cited by 3
Choi, W.-I. (2021) · Precision and Future Medicine · doi:10.23838/pfm.2020.00205 · Cited by 3
Pharmacological Interventions for Pulmonary Involvement in Rheumatic Diseases
Kang, E. H., & Song, Y. W. (2021) · Pharmaceuticals · doi:10.3390/ph14030251 · Cited by 3
Villeneuve, T., Prévôt, G., Lintz, F., Mourin, G., Ferry, G., Bousquet, E., Perelroizen, H., Boghanim, T., Faviez, G., Noël-Savina, É., et al. (2021) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2021.07.004 · Cited by 3
Methotrexate and The Lung in Rheumatoid Arthritis
Nokhatha, S. A. A., Harrington, R., & Conway, R. P. (2020) · EMJ Rheumatology · doi:10.33590/emjrheumatol/20-00074 · Cited by 3
Challenges in the Diagnosis and Management of Patients with Fibrosing Interstitial Lung Disease
Tolle, L. B. (2022) · Case Reports in Pulmonology · doi:10.1155/2022/9942432 · Cited by 3
Progression of Pulmonary Fibrosis According to Radiological Pattern in Asbestosis
Millaire, É., Lévesque, M., Lemière, C., Cartier, A., Provencher, S., & Dion, G. (2022) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202206-474rl · Cited by 3
ERS International Congress 2022: highlights from the Interstitial Lung Diseases Assembly
Karampitsakos, Τ., Diep, P. P., Loth, D. W., Nadeem, I., Khurtsidze, E., Wijsenbeek, M. S., Wuyts, W. A., Bargagli, E., Froidure, A., Spagnolo, P., et al. (2023) · ERJ Open Research · doi:10.1183/23120541.00584-2022 · Cited by 3
Abdalla, M., Castellani, C., Singh, H., Kurman, J. S., & Benn, B. S. (2023) · Respiratory Medicine and Research · doi:10.1016/j.resmer.2023.100996 · Cited by 3
Interstitial lung diseases: an overview
Karampitsakos, Τ., Wijsenbeek, M. S., Herazo‐Maya, J. D., Τzouvelekis, Α., & Kreuter, M. (2023) · European Respiratory Society eBooks · doi:10.1183/2312508x.10017322 · Cited by 3
Munker, D., Arnold, P., Leuschner, G., Irlbeck, M., Michel, S. G., Kauke, T., Meiser, B., Behr, J., Kneidinger, N., & Veit, T. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12154996 · Cited by 3
Unintentional unblinding in rheumatic disease trials
Bruggemeyer, C., Nepal, D., & Putman, M. (2023) · The Lancet Rheumatology · doi:10.1016/s2665-9913(23)00191-1 · Cited by 3
Progressive pulmonary fibrosis associated autoimmune diseases: Systematic review of the literature
Santana, L. J. C., Calderón, D. R. G., Rivera, M. R., Yate, J. A., & Galindo, J. L. (2023) · Revista Colombiana de Reumatología · doi:10.1016/j.rcreu.2023.09.007 · Cited by 3
Pulmonary manifestations of systemic sclerosis
Sarkar, S. (2022) · The Journal of Association of Chest Physicians · doi:10.4103/jacp.jacp_20_22 · Cited by 3
Vaiarello, V., Schiavetto, S., Foti, F., Gigante, A., Iannazzo, F., Paone, G., Palange, P., & Rosato, E. (2020) · Rheumatology and Therapy · doi:10.1007/s40744-020-00232-5 · Cited by 3
Alsharari, D., Obeidat, L. A., Khasawneh, H., Alhmar, M. R. H., Khasawneh, R. M., Bataineh, Z. S., & Al-Dhoun, A. (2020) · Medical Archives · doi:10.5455/medarh.2020.74.450-454 · Cited by 3
Pulmonary Fibrosis in Sarcoidosis
Carmona, E. M., Francesqui, J., & Kalra, S. (2021) · Barcelona Respiratory Network · doi:10.23866/brnrev:2021-m0066 · Cited by 3
Outpatient Pharmacologic Management of Lung Transplant Candidates on the Waiting List
Sayah, D. M., & Pilewski, J. M. (2022) · Thoracic surgery clinics/Thorac. surg. clin. · doi:10.1016/j.thorsurg.2022.01.002 · Cited by 3
Interstitielle Lungenerkrankungen
Lederer, C., Buschulte, K., Hellmich, B., Heußel, C. P., Kriegsmann, M., Polke, M., & Kreuter, M. (2023) · Die Innere Medizin · doi:10.1007/s00108-023-01476-3 · Cited by 3
Bordas-Martínez, J., Llanos-González, A. B., Jódar-Masanés, R., Vicens‐Zygmunt, V., Bermudo, G., Luburich, P., Dorca, J., Molina‐Molina, M., & Suárez-Cuartín, G. (2021) · Open Respiratory Archives · doi:10.1016/j.opresp.2020.100080 · Cited by 3
An update on recent randomized clinical trials in systemic sclerosis
Boleto, G., Avouac, J., & Allanore, Y. (2021) · Joint Bone Spine · doi:10.1016/j.jbspin.2021.105184 · Cited by 3
Drugs that act on the respiratory tract
Yogaratnam, D., Carey, K. M., Coppenrath, V. A., Dawson, A., Havkins, D., LaMothe, A. B. W., & Lynch, A. M. (2020) · Side effects of drugs annual · doi:10.1016/bs.seda.2020.09.014 · Cited by 3
Idiopathic pulmonary fibrosis: accurate diagnosis and early treatment
Morais, A. (2019) · Jornal Brasileiro de Pneumologia · doi:10.1590/1806-3713/e20190353 · Cited by 3
Progressive fibrosing interstitial lung disease: we know it behaves badly, but what does that mean?
Wongkarnjana, A., & Ryerson, C. J. (2020) · European Respiratory Journal · doi:10.1183/13993003.00894-2020 · Cited by 3
Metadata
- Authors
- Distler, O., Highland, K. B., Gahlemann, M., Azuma, A., Fischer, A., Mayes, M. D., Raghu, G., Sauter, W., Girard, M., Alves, M., Clerisme-Beaty, E., Stowasser, S., Tetzlaff, K., Kuwana, M., & Maher, T. M.
- Affiliations
- Cleveland Clinic (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-06-27
- Volume
- 380
- Issue
- 26
- Pages
- 2518-2528
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2945521814
- Cited by
- 1,647
- References
- 36
- Citations by year
- 2026: 139 · 2025: 203 · 2024: 215 · 2023: 231 · 2022: 243 · 2021: 299 · 2020: 247 · 2019: 68
- FWCI
- 157.88
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion, other-oa)
- Digital Access to Libraries (Université catholique de Louvain (UCL), l'Université de Namur (UNamur) and the Université Saint-Louis (USL-B)) (submittedVersion, other-oa)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion, other-oa)
- Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
- CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion, other-oa)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Spiral (Imperial College London) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Boehringer Ingelheim
- Topics
- Health Sciences › Medicine › Rheumatology › Systemic Sclerosis and Related Diseases
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- nintedanib, systemic sclerosis, systemic sclerosis-associated interstitial lung disease, tyrosine kinase inhibitors, antifibrotic therapy, forced vital capacity decline, pulmonary fibrosis, diffuse cutaneous systemic sclerosis, skin involvement, quality of life, diarrhea, adverse events, mycophenolate, modified Rodnan skin score, St George's Respiratory Questionnaire
- MeSH terms
- Administration, Oral, Adult, Diarrhea, Double-Blind Method, Enzyme Inhibitors, Female, Humans, Indoles, Male, Middle Aged, Protein-Tyrosine Kinases, Scleroderma, Systemic, Vital Capacity, Lung Diseases, Interstitial, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
